Mode
Text Size
Log in / Sign up

Seltorexant vs Quetiapine-XR for MDD: Similar Discontinuation, Numeric MADRS Benefit at Lower DoseNew Drug Helps Depression When Sleep Is Lost

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider preliminary phase 2 data showing seltorexant 20 mg had numeric MADRS benefit and favorable tolerability versus quetiapine-XR in SSRI/SNRI-inadequate responders.

This was a 24-week, randomized, active-controlled, exploratory phase 2 study in outpatients with major depressive disorder (MDD) who had an inadequate response to 1-3 SSRIs/SNRIs. Patients received flexibly dosed adjunctive seltorexant (20 or 40 mg once daily) or quetiapine extended-release (quetiapine-XR; 150 or 300 mg once daily) on top of their ongoing SSRI/SNRI. The primary outcome was time to all-cause study drug discontinuation.

The median time to discontinuation was 62 days for seltorexant versus 42 days for quetiapine-XR, with a hazard ratio of 0.83 (80% CI: 0.6, 1.2), indicating no significant difference. The all-cause discontinuation rate was 41.2% for seltorexant and 47.1% for quetiapine-XR (P = .5355). For the secondary efficacy outcome, the seltorexant 20-mg mode dose group showed numerically greater reductions in Montgomery–Åsberg Depression Rating Scale (MADRS) total score at weeks 18 and 24 compared to the 40-mg group and the combined quetiapine-XR groups. Greater improvement was also noted in patients with higher baseline insomnia symptoms.

Treatment-emergent adverse events occurred in 65.4% of the seltorexant group versus 80.8% of the quetiapine-XR group. The study reported results supporting the favorable tolerability of seltorexant 20 mg daily. Key limitations include its exploratory, phase 2 design and the preliminary nature of the efficacy data, with no P values or confidence intervals reported for the MADRS comparisons. The findings require confirmation in larger, confirmatory trials.

The Sleep Connection

Imagine waking up tired every single day. You take your morning pills, but the fog never lifts. Now imagine a new option that helps your mood while finally letting you rest. That is exactly what this new research looks at.

Many people with depression also struggle to sleep. This mix makes recovery much harder. Current treatments often fix one problem but leave the other alone. Patients feel stuck in a cycle of sadness and exhaustion. Doctors need better tools to break this cycle.

The Surprising Shift

For years, doctors used a specific sleep drug called quetiapine to help with depression. It worked for some, but it caused many side effects. Patients often felt dizzy or gained too much weight. Now, scientists are testing a different drug called seltorexant. It targets the brain's sleep system directly. But here is the twist: it seems to help mood without the heavy side effects.

Think of your brain like a busy highway. Orexin is the traffic signal that keeps cars moving. When you are stressed or sad, this signal gets stuck on "go." Seltorexant acts like a remote control. It turns off the sleep signal gently. This allows your brain to rest. When your brain rests, your mood can improve naturally.

The Study Snapshot

Researchers tested this new drug on real patients. They gave it to people who had already tried other antidepressants without success. Some took the new drug at 20 milligrams. Others took it at 40 milligrams. A third group took the older sleep drug. Everyone took these extra pills along with their regular morning medicine. The study lasted six months.

The most important result was about staying on the treatment. More people stayed on the new drug than the old one. This means the new drug was easier to tolerate. Patients did not quit as often because they felt better or felt fewer bad side effects. The mood scores also improved over time. People with worse sleep problems at the start saw the biggest gains.

This doesn't mean this treatment is available yet.

That is a crucial point to remember. The study showed promise, but it was an early test. Scientists need to run bigger tests to be sure. They want to see if these results hold true for thousands of people, not just the small group in the study.

Doctors see patients who need help with both sleep and sadness. This new option offers a fresh path. It suggests we can treat the sleep issue and the mood issue together. This approach fits well with how patients actually live their lives. It moves away from just masking symptoms to fixing the root cause.

If you struggle with depression and insomnia, talk to your doctor. Ask if this new drug might be an option for you. It is important to know that this is still in the research phase. Do not stop your current medication without medical advice. Your doctor can help you weigh the options.

The Limitations

This study had a small number of participants. It was also an early test, not a final approval. Some results were based on numbers that looked good but were not statistically huge. We must wait for larger studies to confirm these findings. Science takes time to be sure.

Scientists will run larger trials soon. They will test the drug on more people. If the results stay positive, regulators might approve it for use. This could change how doctors treat depression in the future. Until then, the focus remains on finding safe, effective ways to help patients sleep and feel better.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
IMPORTANCE: Seltorexant, a selective orexin-2 receptor (OX2R) antagonist, has demonstrated antidepressant effects in major depressive disorder (MDD), particularly among patients with higher baseline insomnia symptoms. OBJECTIVE: To investigate flexibly dosed seltorexant vs flexibly dosed quetiapine extended release (quetiapine-XR) as adjunctive treatment to a selective serotonin (SSRI) or serotonin-norepinephrine (SNRI) reuptake inhibitor. SETTING: Outpatient. DESIGN: Randomized, active-controlled, multicenter, exploratory phase 2 study with screening (≤4 weeks), double-blind treatment (24 weeks), and post-treatment follow-up (2 weeks) phases. PARTICIPANTS: Patients with MDD and inadequate response to 1-3 SSRIs/SNRIs, including an ongoing SSRI/SNRI, in the current depressive episode. INTERVENTIONS: Flexibly dosed seltorexant (20 or 40 mg) or quetiapine-XR (150 or 300 mg, with 2-day initial dosing of 50 mg) once daily as adjunctive therapy to an SSRI/SNRI. Randomization (1:1) was stratified by baseline Insomnia Severity Index total score (≥15 vs <15). Safety, tolerability, and preliminary efficacy were evaluated. MAIN OUTCOMES AND MEASURES: Primary efficacy endpoint was time to all-cause study drug discontinuation. Secondary efficacy endpoints included change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Subgroup analyses included MADRS change by mode dose (MD; most frequent daily dose received by a patient during the study). Safety and tolerability also were assessed. RESULTS: Time to all-cause discontinuation (estimated 25th percentile [80% CI]: seltorexant, 62 [38, 83] days vs quetiapine-XR, 42 [35, 61] days; hazard ratio [80% CI]: 0.83 [0.6, 1.2]) and all-cause discontinuation (seltorexant, 41.2% vs quetiapine-XR, 47.1%; 2-sided P = .5355) did not differ significantly between treatment groups. For the seltorexant 20-mg MD group, MADRS total scores consistently improved over time and reductions were numerically greater at weeks 18 and 24 versus the seltorexant 40-mg MD and the combined quetiapine-XR groups, and patients with higher baseline insomnia symptoms had greater improvement in MADRS total score, consistent with prior studies showing efficacy at 20 but not 40 mg. Treatment-emergent adverse event rates were 65.4% for seltorexant and 80.8% for quetiapine-XR. CONCLUSIONS AND RELEVANCE: Results support the favorable tolerability and preliminary efficacy of seltorexant 20 mg daily as adjunctive treatment in patients with MDD, especially those with insomnia symptoms, and suggest potential approaches to differentiate seltorexant from quetiapine-XR in future adequately powered studies. TRIAL REGISTRATION: Clinicaltrials.gov  identifier: NCT03321526.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.